M&A Deal Summary

Cycle Pharmaceuticals Acquires Vanda Pharmaceuticals

On October 14, 2024, Cycle Pharmaceuticals acquired life science company Vanda Pharmaceuticals

Acquisition Highlights
  • This is Cycle Pharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Cycle Pharmaceuticals’ 1st transaction in the United States.
  • This is Cycle Pharmaceuticals’ 1st transaction in District of Columbia.

M&A Deal Summary
Date 2024-10-14
Target Vanda Pharmaceuticals
Sector Life Science
Buyer(s) Cycle Pharmaceuticals
Deal Type Add-on Acquisition

Target

Vanda Pharmaceuticals

Washington, District of Columbia, United States
Vanda Pharmaceuticals is a bio pharmaceutical company focused on the development and commercialization of innovative therapies. Vanda Pharmaceuticals is based in Washington, District of Columbia.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Cycle Pharmaceuticals

Cambridge, United Kingdom
Category Company
Founded 2012
Sector Life Science
DESCRIPTION

Cycle Pharmaceuticals is a developer of rare disease therapies focuses on rare metabolic, immunological, and neurological genetic conditions. Cycle Pharmaceuticals was founded in 2012 and is based in Cambridge, United Kingdom.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (District of Columbia) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Mergr

Product

Company

Legal